Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics logoAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AIMT
  • CUSIP: N/A
  • Web: www.aimmune.com
Capitalization:
  • Market Cap: $863.37 million
  • Outstanding Shares: 50,342,000
Average Prices:
  • 50 Day Moving Avg: $19.24
  • 200 Day Moving Avg: $20.87
  • 52 Week Range: $9.77 - $27.31
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.24
  • P/E Growth: 0.16
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.26 per share
  • Price / Book: 3.26
Profitability:
  • EBIDTA: ($91,620,000.00)
  • Return on Equity: -132.42%
  • Return on Assets: -37.19%
Debt:
  • Current Ratio: 12.89%
  • Quick Ratio: 12.89%
Misc:
  • Average Volume: 323,359 shs.
  • Beta: -1.23
  • Short Ratio: 10.54
 

Frequently Asked Questions for Aimmune Therapeutics (NASDAQ:AIMT)

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.05. View Aimmune Therapeutics' Earnings History.

Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2017?

4 equities research analysts have issued 1-year price objectives for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $42.00. On average, they anticipate Aimmune Therapeutics' share price to reach $36.25 in the next year. View Analyst Ratings for Aimmune Therapeutics.

What are analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (5/16/2017)
  • 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)

Who are some of Aimmune Therapeutics' key competitors?

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Who owns Aimmune Therapeutics stock?

Aimmune Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Foresite Capital Management II LLC (0.00%), FMR LLC (0.00%), Aisling Capital LLC (0.00%), Wellington Management Group LLP (0.00%), TLP Group LLC (0.00%) and Vanguard Group Inc. (0.00%). Company insiders that own Aimmune Therapeutics stock include Eric Bjerkholt, Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii,, Mary M Rozenman, Stephen George Dilly and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

Who sold Aimmune Therapeutics stock? Who is selling Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, TLP Group LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Public Employees Retirement Association of Colorado, Russell Investments Group Ltd., JPMorgan Chase & Co. and Parametric Portfolio Associates LLC. Company insiders that have sold Aimmune Therapeutics stock in the last year include Foresite Capital Fund Ii, LP, Mary M Rozenman, Stephen George Dilly and Warren L Desouza. View Insider Buying and Selling for Aimmune Therapeutics.

Who bought Aimmune Therapeutics stock? Who is buying Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Palo Alto Investors LLC, Vanguard Group Inc., Eventide Asset Management LLC, State Street Corp, Point72 Asset Management L.P., C WorldWide Group Holding A S and Foresite Capital Management II LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Eric Bjerkholt and Longitude Capital Partners Ii,. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy Aimmune Therapeutics stock?

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aimmune Therapeutics stock cost?

One share of Aimmune Therapeutics stock can currently be purchased for approximately $17.15.

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.25 (111.37% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$38.00LowView Rating Details
2/17/2017WedbushReiterated RatingOutperform$42.00N/AView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/AView Rating Details
8/19/2016Credit Suisse Group AGReiterated RatingBuy$35.00N/AView Rating Details
5/16/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings History by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.57)($0.52)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.47)($0.55)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.45)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
11/4/2015Q3 2015($0.24)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
2017 EPS Consensus Estimate: ($2.64)
2018 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.55)($0.55)($0.55)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.69)($0.69)($0.69)
Q4 20171($0.80)($0.80)($0.80)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 61.61%
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Eric BjerkholtCFOBuy5,000$19.84$99,200.00View SEC Filing  
5/10/2017Stephen George DillyInsiderSell600$20.15$12,090.00View SEC Filing  
4/3/2017Warren L DesouzaCFOSell15,000$21.58$323,700.00View SEC Filing  
3/21/2017Warren L DesouzaCFOSell10,000$22.95$229,500.00View SEC Filing  
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.60View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.00View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.00View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aimmune Therapeutics (NASDAQ:AIMT)
Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
Source:
DateHeadline
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 16 at 8:18 PM
finance.yahoo.com logoWhy These Drug Stocks May Surge
finance.yahoo.com - May 16 at 6:57 AM
americanbankingnews.com logoEric Bjerkholt Acquires 5,000 Shares of Aimmune Therapeutics Inc (AIMT) Stock
www.americanbankingnews.com - May 15 at 7:50 PM
americanbankingnews.com logoInsider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 600 Shares of Stock
www.americanbankingnews.com - May 12 at 8:48 PM
reuters.com logoBRIEF-Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug
www.reuters.com - May 12 at 3:59 PM
americanbankingnews.com logoWedbush Comments on Aimmune Therapeutics Inc's Q2 2017 Earnings (AIMT)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoWedbush Equities Analysts Boost Earnings Estimates for Aimmune Therapeutics Inc (AIMT)
www.americanbankingnews.com - May 11 at 3:58 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Announces Enrollment of First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101
www.streetinsider.com - May 11 at 3:41 PM
finance.yahoo.com logoAimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
finance.yahoo.com - May 11 at 3:41 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Releases Earnings Results
www.americanbankingnews.com - May 9 at 1:38 PM
finance.yahoo.com logoAimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
finance.yahoo.com - May 9 at 9:23 AM
finance.yahoo.com logoAimmune Therapeutics Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:24 PM
marketbeat.com logoAimmune Therapeutics reports 1Q loss
marketbeat.com - May 8 at 4:13 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Receiving Somewhat Critical Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 8:58 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 12:37 PM
finance.yahoo.com logoBiotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo
finance.yahoo.com - May 1 at 3:26 PM
americanbankingnews.com logo Analysts Anticipate Aimmune Therapeutics Inc (AIMT) Will Announce Earnings of -$0.53 Per Share
www.americanbankingnews.com - May 1 at 1:02 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Receives News Sentiment Score of 0.21
www.americanbankingnews.com - April 27 at 9:34 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Earning Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 12:15 PM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Given Media Impact Rating of -0.02
www.americanbankingnews.com - April 21 at 9:05 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Given Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 18 at 10:51 AM
americanbankingnews.com logoAimmune Therapeutics (AIMT) Receives Daily Media Sentiment Score of 0.16
www.americanbankingnews.com - April 15 at 9:45 AM
finance.yahoo.com logoAimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
finance.yahoo.com - April 13 at 8:51 AM
finance.yahoo.com logoShould You Get Rid of Aimmune Therapeutics (AIMT) Now? - Yahoo Finance
finance.yahoo.com - April 11 at 3:26 PM
zacks.com logoShould You Get Rid of Aimmune Therapeutics (AIMT) Now?
www.zacks.com - April 11 at 8:17 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Expected to Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 9 at 7:34 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 8 at 12:50 PM
americanbankingnews.com logo-$0.53 EPS Expected for Aimmune Therapeutics Inc (AIMT) This Quarter
www.americanbankingnews.com - April 7 at 10:24 PM
americanbankingnews.com logoInsider Selling: Aimmune Therapeutics Inc (AIMT) CFO Sells 15,000 Shares of Stock
www.americanbankingnews.com - April 5 at 8:28 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 9:10 AM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) CFO Sells $229,500.00 in Stock
www.americanbankingnews.com - March 23 at 7:33 PM
americanbankingnews.com logoAimmune Therapeutics' (AIMT) Overweight Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - March 22 at 2:26 PM
finance.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Financials
finance.yahoo.com - March 21 at 3:49 PM
americanbankingnews.com logoZacks Investment Research Downgrades Aimmune Therapeutics Inc (AIMT) to Sell
www.americanbankingnews.com - March 20 at 8:33 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Aimmune Therapeutics Inc (AIMT) Cut by Analyst
www.americanbankingnews.com - March 20 at 9:55 AM
finance.yahoo.com logoEdited Transcript of AIMT earnings conference call or presentation 15-Mar-17 12:00pm GMT
finance.yahoo.com - March 16 at 4:58 PM
americanbankingnews.com logoAimmune Therapeutics Inc (AIMT) Issues Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoAimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 16 at 1:36 AM
biz.yahoo.com logoQ4 2016 Aimmune Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 15 at 3:32 PM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - March 15 at 3:32 PM
finance.yahoo.com logoAimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
finance.yahoo.com - March 8 at 3:28 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Presents Data on Phase 3 Screening ... - StreetInsider.com
www.streetinsider.com - March 7 at 6:56 AM
businesswire.com logoAimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology ...
www.businesswire.com - March 6 at 11:21 AM
us.rd.yahoo.com logoAimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
us.rd.yahoo.com - March 6 at 11:21 AM
us.rd.yahoo.com logo9:46 am Aimmune Therapeutics presents clinical data at the 2017 American Academy of Allergy, Asthma & Immunology annual meeting in Atlanta for Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy
us.rd.yahoo.com - March 6 at 11:21 AM
finance.yahoo.com logoAimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 8:20 AM
streetinsider.com logoAimmune Therapeutics (AIMT) to Present AR101 Clinical Data in Peanut Allergy at AAAAI - StreetInsider.com
www.streetinsider.com - February 27 at 3:33 PM
finance.yahoo.com logoAimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
finance.yahoo.com - February 27 at 3:33 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Offers Update on Ongoing AR101 Phase 3 Program for Peanut Allergy - StreetInsider.com
www.streetinsider.com - February 18 at 9:35 AM
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $40 PT on Aimmune Therapeutics (AIMT) Following AR101 Update - StreetInsider.com
www.streetinsider.com - February 18 at 9:35 AM

Social

Chart

Aimmune Therapeutics (AIMT) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff